$0.74
+0.01
(+1.51%)▲
1.32%
Downside
Day's Volatility :8.5%
Upside
7.27%
18.36%
Downside
52 Weeks Volatility :58.34%
Upside
48.97%
Period | Xtant Medical Holdings Inc | Index (Russel 2000) |
---|---|---|
3 Months | -23.37% | 0.0% |
6 Months | -30.0% | 0.0% |
1 Year | -18.75% | 0.0% |
3 Years | -40.81% | -20.2% |
Market Capitalization | 96.2M |
Book Value | $0.37 |
Earnings Per Share (EPS) | 0.0 |
PE Ratio | 0.0 |
PEG Ratio | -0.03 |
Wall Street Target Price | 2.35 |
Profit Margin | -1.64% |
Operating Margin TTM | -12.45% |
Return On Assets TTM | -9.58% |
Return On Equity TTM | -4.14% |
Revenue TTM | 101.2M |
Revenue Per Share TTM | 0.81 |
Quarterly Revenue Growth YOY | 55.300000000000004% |
Gross Profit TTM | 32.1M |
EBITDA | -8.3M |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.08 |
EPS Estimate Next Year | -0.01 |
EPS Estimate Current Quarter | -0.01 |
EPS Estimate Next Quarter | -0.01 |
What analysts predicted
Upside of 217.57%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 72.2M | ↓ 12.6% |
Net Income | -70.1M | ↑ 33.75% |
Net Profit Margin | -97.09% | ↓ 33.65% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 64.7M | ↓ 10.42% |
Net Income | -8.2M | ↓ 88.27% |
Net Profit Margin | -12.71% | ↑ 84.38% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 53.3M | ↓ 17.54% |
Net Income | -7.0M | ↓ 14.57% |
Net Profit Margin | -13.17% | ↓ 0.46% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 55.3M | ↑ 3.61% |
Net Income | -5.8M | ↓ 16.79% |
Net Profit Margin | -10.57% | ↑ 2.6% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 58.0M | ↑ 4.9% |
Net Income | -8.5M | ↑ 45.19% |
Net Profit Margin | -14.64% | ↓ 4.07% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 91.3M | ↑ 57.5% |
Net Income | 660.0K | ↓ 107.78% |
Net Profit Margin | 0.72% | ↑ 15.36% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 15.3M | ↑ 5.59% |
Net Income | -2.2M | ↓ 6.12% |
Net Profit Margin | -14.47% | ↑ 1.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 17.9M | ↑ 17.5% |
Net Income | -2.1M | ↓ 5.93% |
Net Profit Margin | -11.58% | ↑ 2.89% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.2M | ↑ 12.76% |
Net Income | -2.2M | ↑ 5.39% |
Net Profit Margin | -10.82% | ↑ 0.76% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.0M | ↑ 23.66% |
Net Income | 9.2M | ↓ 521.51% |
Net Profit Margin | 36.9% | ↑ 47.72% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 28.1M | ↑ 12.35% |
Net Income | -4.3M | ↓ 146.61% |
Net Profit Margin | -15.31% | ↓ 52.21% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 28.1M | ↑ 0.0% |
Net Income | -4.3M | ↑ 0.0% |
Net Profit Margin | -15.31% | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 46.4M | ↓ 56.08% |
Total Liabilities | 90.2M | ↓ 45.14% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 43.2M | ↓ 7.04% |
Total Liabilities | 87.4M | ↓ 3.14% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 41.5M | ↓ 3.91% |
Total Liabilities | 27.0M | ↓ 69.15% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 54.7M | ↑ 31.9% |
Total Liabilities | 23.8M | ↓ 11.66% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 60.2M | ↑ 10.12% |
Total Liabilities | 26.1M | ↑ 9.45% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 92.6M | ↑ 53.77% |
Total Liabilities | 41.3M | ↑ 58.35% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 60.2M | ↑ 7.46% |
Total Liabilities | 26.1M | ↑ 11.95% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 63.3M | ↑ 5.13% |
Total Liabilities | 30.6M | ↑ 17.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 65.2M | ↑ 3.0% |
Total Liabilities | 34.3M | ↑ 11.94% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 92.0M | ↑ 41.07% |
Total Liabilities | 37.3M | ↑ 8.94% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 92.6M | ↑ 0.66% |
Total Liabilities | 41.3M | ↑ 10.56% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 92.6M | ↑ 0.0% |
Total Liabilities | 41.3M | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2M | ↓ 323.13% |
Investing Cash Flow | -367.0K | ↓ 77.18% |
Financing Cash Flow | 3.1M | ↑ 27.46% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -413.0K | ↓ 134.08% |
Investing Cash Flow | -544.0K | ↑ 48.23% |
Financing Cash Flow | -603.0K | ↓ 119.48% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -731.0K | ↑ 77.0% |
Investing Cash Flow | -1.3M | ↑ 139.71% |
Financing Cash Flow | -861.0K | ↑ 42.79% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 439.0K | ↓ 160.05% |
Investing Cash Flow | -1.9M | ↑ 44.94% |
Financing Cash Flow | 17.5M | ↓ 2132.17% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.3M | ↓ 1316.63% |
Investing Cash Flow | -1.6M | ↓ 17.51% |
Financing Cash Flow | 9.0M | ↓ 48.45% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.3M | ↑ 10.85% |
Investing Cash Flow | -422.0K | ↓ 14.23% |
Financing Cash Flow | 5.6M | ↑ 69.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.2M | ↓ 1.88% |
Investing Cash Flow | -17.4M | ↑ 4028.2% |
Financing Cash Flow | 4.6M | ↓ 18.61% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.5M | ↑ 12.29% |
Investing Cash Flow | -394.0K | ↓ 97.74% |
Financing Cash Flow | 2.0M | ↓ 57.26% |
Sell
Neutral
Buy
Xtant Medical Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Xtant Medical Holdings Inc | 16.48% | -30.0% | -18.75% | -40.81% | -74.09% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Xtant Medical Holdings Inc | 0.0 | 0.0 | -0.03 | -0.08 | -0.04 | -0.1 | NA | 0.37 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Xtant Medical Holdings Inc | Buy | $96.2M | -74.09% | 0.0 | -1.64% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Xtant Medical Holdings Inc
Revenue is up for the last 7 quarters, 14.46M → 28.10M (in $), with an average increase of 10.3% per quarter
Netprofit is down for the last 3 quarters, 9.23M → -4.30M (in $), with an average decrease of 73.3% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 60.5%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 109.7%
xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.
Organization | Xtant Medical Holdings Inc |
Employees | 207 |
CEO | Mr. Sean E. Browne |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.74
+1.51%
Keyarch Acquisition Corp
$0.74
+1.51%
Connexa Sports Technologies Inc
$0.74
+1.51%
Us Value Etf
$0.74
+1.51%
First Wave Biopharma Inc
$0.74
+1.51%
Global X Msci Next Emerging
$0.74
+1.51%
Fat Projects Acquisition Corp
$0.74
+1.51%
Capital Link Global Fintech
$0.74
+1.51%
Applied Uv Inc
$0.74
+1.51%